• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA names new deputy commissioner for medical products and tobacco

FDA names new deputy commissioner for medical products and tobacco

July 15, 2011
CenterWatch Staff

The FDA has named former Dartmouth Medical School Dean Stephen Spielberg to the newly created position of deputy commissioner for medical products and tobacco, according to an internal letter sent to FDA employees obtained by Reuters.

The move is part of the FDA's goal to overhaul its management structure to better regulate an increasingly complex medical industry. The agency has also initiated a search to fill the newly created chief operating officer position, according to Reuters.

FDA Commissioner Margaret Hamburg promoted Deborah Autor, currently a director of the agency's compliance office, to the job of deputy commissioner for global regulatory operations and policy, according to the letter.

"The new organizational alignments more accurately reflect the agency's responsibilities, subject matter expertise and mandates in an ever more complex world, where products and services do not fit into a single category," Hamburg wrote in the letter.

Earlier this year, former Deputy Commissioner Joshua Sharfstein, who was appointed by President Barack Obama in 2009, left the agency to run the state of Maryland's health department. Under Hamburg and Sharfstein, the agency had become more aggressive in its oversight of companies for product-safety problems, shoddy manufacturing and misleading advertisements.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing